Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2018-12-06
Target enrollment:
Participant gender:
Summary
This study will evaluate the long-term safety and tolerability of rapastinel as an adjunctive
to antidepressant therapy (ADT) in patients with major depressive disorder (MDD).
Phase:
Phase 3
Details
Lead Sponsor:
Allergan Naurex, Inc, an affiliate of Allergan plc